Redefining Sight for Life.®
  • About Us
    • Our Global Mission
    • Core Values
    • Sustainability
    • Leadership Team
  • Our Technology
    • Reimagining Ocular Gene Therapy
    • Therapeutic Protein Biofactories
    • Sustained Protein Expression
    • Efficient, Scalable Manufacturing
  • Pipeline
    • Our Programs
    • Ixo-vec
  • For Patients & Caregivers
    • Overview
    • Resources
    • Our Commitment
    • Patient Stories
    • Expanded Access Policy
    • Ixo-vec ARTEMIS wAMD Trial
  • Publications, Scientific
    Presentations, & Archived
    Press Releases
    • Publications
    • Archived Press Releases
  • Contact Us
SF Top Work Places Award
Adverum Biotechnologies
Contact Us

The Blog of Laurent Fischer, M.D.

Seeing Beyond

Laurent Fischer, MD

Chief Executive Officer – Adverum

Cras Commodo Pharetra Ornare Inceptos Cras Commodo Pharetra Ornare Inceptos
February 12th, 2020
Ligula Consectetur Nibh Quam PurusLigula Consectetur
March 27th, 2020
Ornare Parturient Ligula Bibendum Porta Ornare Parturient Ligula Bibendum Porta
August 6th, 2020
[ajax_load_more scroll="false" post-type="post" posts_per_page="12"]
We are driven to establish gene therapy as a new standard of care for the leading causes of vision loss.
About Us
Our Technology
Pipeline
For Patients & Caregivers
Scientific Presentations & Publications
Contact Us

We are driven to establish gene therapy as a new standard of care for the leading causes of vision loss.

Copyright © 2026 Lilly. All rights reserved.
Terms of Use | Privacy Statement | Accessibility Statement

Adverum Biotechnologies, Inc.
100 Cardinal Way, Redwood City, CA 94063

Tel: 650-656-9323Fax: 650-649-1995

Designed by Elegant Themes | Powered by WordPress

  • Privacy Policy
  • Community Guidelines
You Are Now Leaving adverum.com

You’ve clicked on a link for a third-party site, which Adverum Biotechnologies, Inc. does not control, influence, or endorse. Adverum is not responsible for any content on this third-party site, including the privacy policy.

GO BACK
CONTINUE